Study of rituximab efficacy, cost, safety, and compliance of its package leaflet in a tertiary hospital
Estudio de adecuación a la ficha técnica, efectividad, seguridad y coste del rituximab en un hospital de tercer nivel
Leído
2266
Vecesse ha leído el artículo
1104
Total PDF
1162
Total HTML
| año/Mes | Html | Total | |
|---|---|---|---|
| 2025 6 | 13 | 12 | 25 |
| 2025 5 | 48 | 23 | 71 |
| 2025 4 | 44 | 29 | 73 |
| 2025 3 | 59 | 18 | 77 |
| 2025 2 | 57 | 36 | 93 |
| 2025 1 | 31 | 29 | 60 |
| 2024 12 | 27 | 14 | 41 |
| 2024 11 | 40 | 25 | 65 |
| 2024 10 | 28 | 21 | 49 |
| 2024 9 | 43 | 23 | 66 |
| 2024 8 | 58 | 31 | 89 |
| 2024 7 | 20 | 31 | 51 |
| 2024 6 | 25 | 17 | 42 |
| 2024 5 | 20 | 18 | 38 |
| 2024 4 | 16 | 11 | 27 |
| 2024 3 | 27 | 28 | 55 |
| 2024 2 | 24 | 28 | 52 |
| 2024 1 | 20 | 20 | 40 |
| 2023 12 | 22 | 22 | 44 |
| 2023 11 | 26 | 34 | 60 |
| 2023 10 | 21 | 24 | 45 |
| 2023 9 | 45 | 32 | 77 |
| 2023 8 | 18 | 16 | 34 |
| 2023 7 | 13 | 23 | 36 |
| 2023 6 | 15 | 18 | 33 |
| 2023 5 | 15 | 23 | 38 |
| 2023 4 | 7 | 33 | 40 |
| 2023 3 | 14 | 38 | 52 |
| 2023 2 | 8 | 14 | 22 |
| 2022 1 | 7 | 10 | 17 |
| 2022 12 | 12 | 5 | 17 |
| 2022 11 | 14 | 12 | 26 |
| 2022 10 | 7 | 7 | 14 |
| 2022 9 | 8 | 9 | 17 |
| 2022 8 | 14 | 13 | 27 |
| 2022 7 | 9 | 6 | 15 |
| 2022 6 | 16 | 13 | 29 |
| 2022 5 | 10 | 6 | 16 |
| 2022 4 | 8 | 10 | 18 |
| 2022 3 | 8 | 6 | 14 |
| 2022 2 | 5 | 6 | 11 |
| 2021 1 | 6 | 5 | 11 |
| 2021 12 | 3 | 12 | 15 |
| 2021 11 | 3 | 11 | 14 |
| 2021 10 | 8 | 10 | 18 |
| 2021 9 | 5 | 9 | 14 |
| 2021 8 | 2 | 6 | 8 |
| 2021 7 | 4 | 8 | 12 |
| 2021 6 | 2 | 6 | 8 |
| 2021 5 | 3 | 6 | 9 |
| 2021 4 | 14 | 8 | 22 |
| 2021 3 | 7 | 6 | 13 |
| 2021 2 | 1 | 5 | 6 |
| 2020 1 | 7 | 8 | 15 |
| 2020 12 | 4 | 7 | 11 |
| 2020 11 | 3 | 8 | 11 |
| 2020 10 | 10 | 4 | 14 |
| 2020 9 | 6 | 6 | 12 |
| 2020 8 | 7 | 2 | 9 |
| 2020 7 | 3 | 4 | 7 |
| 2020 6 | 4 | 3 | 7 |
| 2020 5 | 0 | 3 | 3 |
| 2020 4 | 2 | 2 | 4 |
| 2020 3 | 4 | 7 | 11 |
| 2020 2 | 1 | 3 | 4 |
| 2020 1 | 2 | 6 | 8 |
| 2019 12 | 4 | 11 | 15 |
| 2019 11 | 3 | 8 | 11 |
| 2019 10 | 2 | 7 | 9 |
| 2019 9 | 0 | 9 | 9 |
| 2019 8 | 0 | 13 | 13 |
| 2019 7 | 3 | 11 | 14 |
| 2019 6 | 10 | 5 | 15 |
| 2019 5 | 21 | 4 | 25 |
| 2019 4 | 1 | 5 | 6 |
| 2019 3 | 0 | 1 | 1 |
| 2019 2 | 4 | 3 | 7 |
| 2018 12 | 0 | 3 | 3 |
| 2018 11 | 0 | 2 | 2 |
| 2018 10 | 2 | 7 | 9 |
| 2018 9 | 3 | 5 | 8 |
| 2018 8 | 3 | 2 | 5 |
| 2018 6 | 0 | 5 | 5 |
| 2018 5 | 1 | 4 | 5 |
| 2018 4 | 3 | 11 | 14 |
| 2018 3 | 1 | 2 | 3 |
| 2018 2 | 2 | 0 | 2 |
| 2018 1 | 1 | 2 | 3 |
| 2017 12 | 4 | 1 | 5 |
| 2017 11 | 4 | 3 | 7 |
| 2017 10 | 2 | 2 | 4 |
| 2017 9 | 3 | 2 | 5 |
| 2017 8 | 4 | 10 | 14 |
| 2017 7 | 1 | 1 | 2 |
| 2017 6 | 8 | 2 | 10 |
| 2017 5 | 6 | 2 | 8 |
| 2017 4 | 9 | 4 | 13 |
| 2017 3 | 11 | 5 | 16 |
| 2017 2 | 10 | 1 | 11 |
| 2016 1 | 1 | 0 | 1 |
| 2016 10 | 2 | 2 | 4 |
Mostrar todo
